FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3091909799> ?p ?o ?g. }

• W3091909799 endingPage "419" @default.
• W3091909799 startingPage "409" @default.
• W3091909799 abstract "Abstract Purpose To study the association between interacting drugs and bleeding or thromboembolism in atrial fibrillation outpatients treated with non-vitamin K antagonist oral anticoagulants (NOACs). Methods Population-based cohort study of outpatients treated with NOACs in Sweden from 2008 to 2017. Patients with atrial fibrillation and newly initiated NOAC treatment were identified in the Prescribed Drug Register. Comorbidities and outcome data were retrieved from the Patient Register and the Cause of Death Register. Cox-regression analyses were performed to evaluate the primary endpoints any severe bleed and ischemic stroke/transient ischemic attack/stroke unspecified during the first six months of treatment. Secondary endpoints were gastrointestinal bleeding, intracranial bleeding, ischemic stroke, and venous thromboembolism. Results Increased risk of any severe bleed was found when NOAC treatment, and drugs with pharmacodynamic effect on bleeding were combined, compared to NOAC only. An increased risk with these combinations was evident for apixaban (hazard ratio (HR) 1.47; 95% CI 1.33–1.63), rivaroxaban (HR 1.7; 95% CI 1.49–1.92), and dabigatran (HR 1.26; 95% CI 1.05–1.52). For apixaban, there was an increased risk of any severe bleed when combined with CYP3A4 and/or P-glycoprotein (P-gp) inhibitors (HR 1.23; 95% CI 1.01–1.5). The use of inducers of CYP3A4 and/or P-gp was low in this cohort, and effects on ischemic stroke/TIA/stroke unspecified could not be established. Conclusion Increased risk of bleeding was seen for pharmacodynamic and pharmacokinetic interactions with NOACs. Prescribers need to be vigilant of the effect of interacting drugs on the risk profile of patients treated with NOACs." @default.
• W3091909799 created "2020-10-15" @default.
• W3091909799 creator A5017537112 @default.
• W3091909799 creator A5025181675 @default.
• W3091909799 creator A5065073643 @default.
• W3091909799 creator A5086342867 @default.
• W3091909799 creator A5087188275 @default.
• W3091909799 date "2020-10-07" @default.
• W3091909799 modified "2023-10-18" @default.
• W3091909799 title "Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants—a Swedish, register-based cohort study in atrial fibrillation outpatients" @default.
• W3091909799 cites W1422496566 @default.
• W3091909799 cites W1834574045 @default.
• W3091909799 cites W1981395380 @default.
• W3091909799 cites W1984486655 @default.
• W3091909799 cites W1991833417 @default.
• W3091909799 cites W2029445248 @default.
• W3091909799 cites W2047731840 @default.
• W3091909799 cites W2109850996 @default.
• W3091909799 cites W2127985968 @default.
• W3091909799 cites W2152623033 @default.
• W3091909799 cites W2162586165 @default.
• W3091909799 cites W2164861810 @default.
• W3091909799 cites W2168021466 @default.
• W3091909799 cites W2219896033 @default.
• W3091909799 cites W2435303807 @default.
• W3091909799 cites W2604558540 @default.
• W3091909799 cites W2608749797 @default.
• W3091909799 cites W2764121201 @default.
• W3091909799 cites W2789495441 @default.
• W3091909799 cites W2790058650 @default.
• W3091909799 cites W2791298449 @default.
• W3091909799 cites W2792771303 @default.
• W3091909799 cites W2792857103 @default.
• W3091909799 cites W2808897013 @default.
• W3091909799 cites W2972317421 @default.
• W3091909799 cites W2982707371 @default.
• W3091909799 cites W3005123828 @default.
• W3091909799 doi "https://doi.org/10.1007/s00228-020-03015-7" @default.
• W3091909799 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7867544" @default.
• W3091909799 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33029651" @default.
• W3091909799 hasPublicationYear "2020" @default.
• W3091909799 type Work @default.
• W3091909799 sameAs 3091909799 @default.
• W3091909799 citedByCount "16" @default.
• W3091909799 countsByYear W30919097992021 @default.
• W3091909799 countsByYear W30919097992022 @default.
• W3091909799 countsByYear W30919097992023 @default.
• W3091909799 crossrefType "journal-article" @default.
• W3091909799 hasAuthorship W3091909799A5017537112 @default.
• W3091909799 hasAuthorship W3091909799A5025181675 @default.
• W3091909799 hasAuthorship W3091909799A5065073643 @default.
• W3091909799 hasAuthorship W3091909799A5086342867 @default.
• W3091909799 hasAuthorship W3091909799A5087188275 @default.
• W3091909799 hasBestOaLocation W30919097991 @default.
• W3091909799 hasConcept C111113717 @default.
• W3091909799 hasConcept C112705442 @default.
• W3091909799 hasConcept C126322002 @default.
• W3091909799 hasConcept C127413603 @default.
• W3091909799 hasConcept C141071460 @default.
• W3091909799 hasConcept C207103383 @default.
• W3091909799 hasConcept C2776259030 @default.
• W3091909799 hasConcept C2776301958 @default.
• W3091909799 hasConcept C2776704044 @default.
• W3091909799 hasConcept C2778661090 @default.
• W3091909799 hasConcept C2778810321 @default.
• W3091909799 hasConcept C2779161974 @default.
• W3091909799 hasConcept C2780290652 @default.
• W3091909799 hasConcept C2780638905 @default.
• W3091909799 hasConcept C2780645631 @default.
• W3091909799 hasConcept C2908647359 @default.
• W3091909799 hasConcept C44249647 @default.
• W3091909799 hasConcept C71924100 @default.
• W3091909799 hasConcept C72563966 @default.
• W3091909799 hasConcept C78519656 @default.
• W3091909799 hasConcept C99454951 @default.
• W3091909799 hasConceptScore W3091909799C111113717 @default.
• W3091909799 hasConceptScore W3091909799C112705442 @default.
• W3091909799 hasConceptScore W3091909799C126322002 @default.
• W3091909799 hasConceptScore W3091909799C127413603 @default.
• W3091909799 hasConceptScore W3091909799C141071460 @default.
• W3091909799 hasConceptScore W3091909799C207103383 @default.
• W3091909799 hasConceptScore W3091909799C2776259030 @default.
• W3091909799 hasConceptScore W3091909799C2776301958 @default.
• W3091909799 hasConceptScore W3091909799C2776704044 @default.
• W3091909799 hasConceptScore W3091909799C2778661090 @default.
• W3091909799 hasConceptScore W3091909799C2778810321 @default.
• W3091909799 hasConceptScore W3091909799C2779161974 @default.
• W3091909799 hasConceptScore W3091909799C2780290652 @default.
• W3091909799 hasConceptScore W3091909799C2780638905 @default.
• W3091909799 hasConceptScore W3091909799C2780645631 @default.
• W3091909799 hasConceptScore W3091909799C2908647359 @default.
• W3091909799 hasConceptScore W3091909799C44249647 @default.
• W3091909799 hasConceptScore W3091909799C71924100 @default.
• W3091909799 hasConceptScore W3091909799C72563966 @default.
• W3091909799 hasConceptScore W3091909799C78519656 @default.
• W3091909799 hasConceptScore W3091909799C99454951 @default.
• W3091909799 hasFunder F4320325238 @default.
• W3091909799 hasIssue "3" @default.

• next